QQQ   359.88 (-2.83%)
AAPL   142.06 (-2.28%)
MSFT   284.98 (-3.12%)
FB   340.06 (-3.82%)
GOOGL   2,709.04 (-3.98%)
TSLA   778.07 (-1.68%)
AMZN   3,296.95 (-3.20%)
NVDA   207.01 (-4.43%)
BABA   150.32 (+0.09%)
NIO   35.16 (-4.38%)
CGC   14.19 (-3.54%)
GE   105.19 (-0.15%)
MU   73.42 (-2.34%)
AMD   102.44 (-5.29%)
T   27.22 (-0.66%)
F   14.37 (+1.48%)
ACB   6.75 (+5.63%)
DIS   174.20 (-2.28%)
PFE   42.84 (-1.68%)
BA   218.59 (-2.48%)
AMC   37.49 (-4.61%)
QQQ   359.88 (-2.83%)
AAPL   142.06 (-2.28%)
MSFT   284.98 (-3.12%)
FB   340.06 (-3.82%)
GOOGL   2,709.04 (-3.98%)
TSLA   778.07 (-1.68%)
AMZN   3,296.95 (-3.20%)
NVDA   207.01 (-4.43%)
BABA   150.32 (+0.09%)
NIO   35.16 (-4.38%)
CGC   14.19 (-3.54%)
GE   105.19 (-0.15%)
MU   73.42 (-2.34%)
AMD   102.44 (-5.29%)
T   27.22 (-0.66%)
F   14.37 (+1.48%)
ACB   6.75 (+5.63%)
DIS   174.20 (-2.28%)
PFE   42.84 (-1.68%)
BA   218.59 (-2.48%)
AMC   37.49 (-4.61%)
QQQ   359.88 (-2.83%)
AAPL   142.06 (-2.28%)
MSFT   284.98 (-3.12%)
FB   340.06 (-3.82%)
GOOGL   2,709.04 (-3.98%)
TSLA   778.07 (-1.68%)
AMZN   3,296.95 (-3.20%)
NVDA   207.01 (-4.43%)
BABA   150.32 (+0.09%)
NIO   35.16 (-4.38%)
CGC   14.19 (-3.54%)
GE   105.19 (-0.15%)
MU   73.42 (-2.34%)
AMD   102.44 (-5.29%)
T   27.22 (-0.66%)
F   14.37 (+1.48%)
ACB   6.75 (+5.63%)
DIS   174.20 (-2.28%)
PFE   42.84 (-1.68%)
BA   218.59 (-2.48%)
AMC   37.49 (-4.61%)
QQQ   359.88 (-2.83%)
AAPL   142.06 (-2.28%)
MSFT   284.98 (-3.12%)
FB   340.06 (-3.82%)
GOOGL   2,709.04 (-3.98%)
TSLA   778.07 (-1.68%)
AMZN   3,296.95 (-3.20%)
NVDA   207.01 (-4.43%)
BABA   150.32 (+0.09%)
NIO   35.16 (-4.38%)
CGC   14.19 (-3.54%)
GE   105.19 (-0.15%)
MU   73.42 (-2.34%)
AMD   102.44 (-5.29%)
T   27.22 (-0.66%)
F   14.37 (+1.48%)
ACB   6.75 (+5.63%)
DIS   174.20 (-2.28%)
PFE   42.84 (-1.68%)
BA   218.59 (-2.48%)
AMC   37.49 (-4.61%)
NASDAQ:PTPI

Petros Pharmaceuticals Stock Forecast, Price & News

$1.91
-0.04 (-2.05 %)
(As of 09/28/2021 09:47 AM ET)
Add
Compare
Today's Range
$1.91
$1.91
50-Day Range
$1.84
$3.18
52-Week Range
$1.80
$5.96
Volume1,100 shs
Average Volume120,771 shs
Market Capitalization$18.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87
30 days | 90 days | 365 days | Advanced Chart
Receive PTPI News and Ratings via Email

Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTPI
CIK
N/A
Employees
27
Year Founded
N/A

Sales & Book Value

Annual Sales
$9.56 million
Book Value
$1.79 per share

Profitability

Net Income
$-20,590,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$18.77 million
Next Earnings Date
11/16/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1325th out of 1,353 stocks

Pharmaceutical Preparations Industry

650th out of 666 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Petros Pharmaceuticals (NASDAQ:PTPI) Frequently Asked Questions

What stocks does MarketBeat like better than Petros Pharmaceuticals?

Wall Street analysts have given Petros Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Petros Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Petros Pharmaceuticals' next earnings date?

Petros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 16th 2021.
View our earnings forecast for Petros Pharmaceuticals
.

How were Petros Pharmaceuticals' earnings last quarter?

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) posted its earnings results on Tuesday, August, 17th. The company reported ($0.45) EPS for the quarter. The company earned $2.46 million during the quarter.
View Petros Pharmaceuticals' earnings history
.

Who are Petros Pharmaceuticals' key executives?

Petros Pharmaceuticals' management team includes the following people:
  • Mr. John D. Shulman, Exec. Chairman (Age 58)
  • Mr. Fady Boctor M.B.A., Pres & Chief Commercial Officer (Age 43)
  • Mr. Mitchell S. Arnold M.B.A., VP of Fin. & Chief Accounting Officer (Age 57)
  • Mr. Keith F. Lavan, Advisor (Age 57)
  • Mr. Andrew Gesek M.B.A., Pres of Timm Medical (Age 50)

What is Petros Pharmaceuticals' stock symbol?

Petros Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTPI."

Who are Petros Pharmaceuticals' major shareholders?

Petros Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Shay Capital LLC (2.44%), NorthRock Partners LLC (2.24%), Vanguard Group Inc. (1.10%), CM Management LLC (1.02%), Renaissance Technologies LLC (0.56%) and Platform Technology Partners (0.45%).

Which major investors are selling Petros Pharmaceuticals stock?

PTPI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, NorthRock Partners LLC, and Shay Capital LLC.

Which major investors are buying Petros Pharmaceuticals stock?

PTPI stock was bought by a variety of institutional investors in the last quarter, including CM Management LLC, Platform Technology Partners, Vanguard Group Inc., Virtu Financial LLC, and Geode Capital Management LLC.

How do I buy shares of Petros Pharmaceuticals?

Shares of PTPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Petros Pharmaceuticals' stock price today?

One share of PTPI stock can currently be purchased for approximately $1.91.

How much money does Petros Pharmaceuticals make?

Petros Pharmaceuticals has a market capitalization of $18.77 million and generates $9.56 million in revenue each year.

How many employees does Petros Pharmaceuticals have?

Petros Pharmaceuticals employs 27 workers across the globe.

What is Petros Pharmaceuticals' official website?

The official website for Petros Pharmaceuticals is www.petrospharma.com.

Where are Petros Pharmaceuticals' headquarters?

Petros Pharmaceuticals is headquartered at 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036.

How can I contact Petros Pharmaceuticals?

Petros Pharmaceuticals' mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.